Parallel Bio is a biotechnology company focused on drug discovery through the development of a scalable human immune organoid platform. This technology replicates the human immune system in a laboratory setting, aiming to generate population-scale biological data for pharmaceutical research. The platform is designed to create the first comprehensive map of human biology, using organoid technology, artificial intelligence, and immunology.
The company's primary product, the Scalable Human Immune Organoid Platform, has been used to test over 50 compounds and models more than 170 unique patient backgrounds. The platform achieves 87% concordance with clinical patient data, a metric indicating its potential reliability for generating predictive human-relevant results in drug discovery.
Parallel Bio's work sits at the intersection of pharmaceutical development, immunotherapies, and advanced computational methods. By providing a tool that replicates human immune responses at scale, the company supports the development and testing of new therapies outside of traditional, slower-paced clinical trial models.
